Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Viking Therapeutics, Inc.

Biotech SG&A Expenses: Neurocrine vs. Viking

__timestampNeurocrine Biosciences, Inc.Viking Therapeutics, Inc.
Wednesday, January 1, 2014179860001244910
Thursday, January 1, 2015324800005029636
Friday, January 1, 2016680810004846776
Sunday, January 1, 20171699060005329003
Monday, January 1, 20182489320007121000
Tuesday, January 1, 20193541000009128000
Wednesday, January 1, 202043330000010731000
Friday, January 1, 202158330000010701000
Saturday, January 1, 202275270000016121000
Sunday, January 1, 202388760000037021000
Monday, January 1, 20241007200000
Loading chart...

In pursuit of knowledge

Navigating SG&A Expenses: A Tale of Two Biotechs

In the competitive landscape of biotechnology, effective cost management is crucial. Over the past decade, Neurocrine Biosciences, Inc. and Viking Therapeutics, Inc. have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. Neurocrine Biosciences has seen a staggering 4,800% increase in SG&A expenses from 2014 to 2023, reflecting its aggressive growth and expansion strategies. In contrast, Viking Therapeutics, while also experiencing growth, has maintained a more conservative increase of approximately 2,900% over the same period. This divergence highlights the varied strategic approaches within the biotech sector. As of 2023, Neurocrine's SG&A expenses are nearly 24 times higher than those of Viking, underscoring its larger operational scale. These insights provide a window into how these companies allocate resources to support their business objectives, offering valuable lessons for investors and industry stakeholders alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025